32 results about "Arg-Gly-Asp-Val" patented technology

The invention discloses RGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones, which are three novel conjugates of carbolino-hexahydropyrazine-1,4-diketone and RGD tetrapeptide and are shown in the general formula I. In the general formula I, R represents Arg-Gly-Asp-Val, Arg-Gly-Asp-Phe or Arg-Gly-Asp-Ser. The invention also discloses heterocyclic nucleuses of the novel conjugates, wherein R represents OH. The invention also discloses a preparation method and in-vitro anti-platelet aggregation effects of the novel conjugates, and also discloses an antithrombotic use of the novel conjugates in a rat thrombus formation model. A result shows that the three novel conjugates of carbolino-hexahydropyrazine-1,4-diketone and RGD tetrapeptide (wherein R represents Arg-Gly-Asp-Val, Arg-Gly-Asp-Phe or Arg-Gly-Asp-Ser) and their heterocyclic nucleuses (wherein R represents OH) have good antithrombotic activity and clear application prospects in antithrombotic agent preparation.

The invention discloses a pentamethoxytryptophanylcarbonylpropionyl-RPAK peptide, and a preparation method, activities and applications thereof, and concretely relates to a pentamethoxytryptophanylcarbonylpropionyl-Lys(Arg-Pro-Ala-Lys)-Arg-Gly-Asp-Val with the formula shown in the description, a preparation method thereof, an antithrombotic activity and a thrombus dissolving activity of the pentamethoxytryptophanylcarbonylpropionyl-Lys(Arg-Pro-Ala-Lys)-Arg-Gly-Asp-Val, and an application of the pentamethoxytryptophanylcarbonylpropionyl-Lys(Arg-Pro-Ala-Lys)-Arg-Gly-Asp-Val in the treatment of stroke rats. The invention also discloses an application of the pentamethoxytryptophanylcarbonylpropionyl-Lys(Arg-Pro-Ala-Lys)-Arg-Gly-Asp-Val in the preparation of antithrombotic medicines, thrombus dissolving medicines and ischemic stroke treatment medicines.

The invention relates to cyclic peptides for inhibiting the proliferation of alpha v beta 3 positive cells in a target direction and the preparation and application thereof. The cyclic peptide has an amino acid sequence as follows: Cys Arg Gly Asp Val Cit Arg Leu Arg Trp Arg Lys Cys, wherein, Cys at the end of N and Cys at the end of C form a ring through a disulfide bond.

Aspirin‑Arg‑Gly‑Asp‑Val conjugate, its synthesis, nanostructure and application as a drug delivery system. The invention discloses a novel aspirin-Arg-Gly-Asp-Val (A-RGDV) conjugate, its preparation method and its application as an antithrombotic agent. A-RGDV is characterized in that it can be selectively transported in the blood as nanoparticles, and after reaching the site of thrombus formation, it interacts with the GPIIb / IIIa receptors on the surface of activated platelets to release aspirin. Therefore, A‑RGDV is a targeted drug delivery system for aspirin. A‑RGDV has strong antithrombotic activity and has good clinical application prospects. The following is the structural formula of A‑RGDV. .

The invention discloses a pentamethoxytryptophanylcarbonylpropionyl-Lys(Pro-Ala-Lys)-Arg-Gly-Asp-Val with the formula shown in the description, a preparation method thereof, an antithrombotic activity and a thrombus dissolving activity of the pentamethoxytryptophanylcarbonylpropionyl-Lys(Pro-Ala-Lys)-Arg-Gly-Asp-Val, and an application of the pentamethoxytryptophanylcarbonylpropionyl-Lys(Pro-Ala-Lys)-Arg-Gly-Asp-Val in the treatment of stroke rats. The invention also discloses an application of the pentamethoxytryptophanylcarbonylpropionyl-Lys(Pro-Ala-Lys)-Arg-Gly-Asp-Val in the preparation of antithrombotic medicines, thrombus dissolving medicines and ischemic stroke treatment medicines.

The invention discloses an Arg-Gly-Asp-Val-The-Gly-Arg-Pro-Ala-Lys decapeptide and its preparation method and activity of ischemic stroke treatment, thrombus formation resistance and thrombus dissolution. The invention discloses a use of the Arg-Gly-Asp-Val-The-Gly-Arg-Pro-Ala-Lys decapeptide in preparation of drugs for treating ischemic stroke, resisting thrombus formation and dissolving thrombus.

The invention discloses KRGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones, which are three novel conjugates of carbolino-hexahydropyrazine-1,4-diketone and RGD peptide and are shown in the general formula I. In the general formula I, R represents Lys-Arg-Gly-Asp-Val, Lys-Arg-Gly-Asp-Phe or Lys-Arg-Gly-Asp-Ser. The invention also discloses heterocyclic nucleuses of the novel conjugates, wherein R represents OH. The invention also discloses a preparation method and in-vitro anti-platelet aggregation effects of the novel conjugates, and also discloses an antithrombotic use of the novel conjugates in a rat thrombus formation model. A result shows that the three novel conjugates of carbolino-hexahydropyrazine-1,4-diketone and RGD peptide (wherein R represents Lys-Arg-Gly-Asp-Val, Lys-Arg-Gly-Asp-Phe or Lys-Arg-Gly-Asp-Ser) and their heterocyclic nucleuses (wherein R represents OH) have good antithrombotic activity and clear application prospects in antithrombotic agent preparation.